Online inquiry

IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12796MR)

This product GTTS-WQ12796MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH2&NOTCH3 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001200001.2; NM_000435.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4853; 4854
UniProt ID Q04721; Q9UM47
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12796MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7601MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ891MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ456MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ767MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ2069MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ5063MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ2074MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW